insights_auto
Why is CNSY up 7.82%?
Dive Deeperchevron_right
CNSY:NASDAQ
Cerenome, Inc.
$1.93
arrow_upward
+7.82%(+0.14) 1D
Oct 9, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CNSY...
Open
$1.80
High
$1.96
Low
$1.80
Mkt. cap
14.65M
Avg. vol.
145.04K
Volume
152.09K
52-wk high
$4.16
52-wk low
$1.48
EPS
-$4.42
Beta
1.47
Shares outstanding
7.59M
No. of employees
28
Open
$1.80
High
$1.96
Low
$1.80
Mkt. cap
14.65M
Avg. vol.
145.04K
Volume
152.09K
52-wk high
$4.16
52-wk low
$1.48
EPS
-$4.42
Beta
1.47
Shares outstanding
7.59M
No. of employees
28
News stories
From web sources and news partners
GlobeNewswire
·
1 hour ago
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
TradingView
·
39 minutes ago
TRex Bio, Clinical-Stage Immunology Biopharma, Files for Nasdaq Global Select Market IPO
Quiver Quantitative
·
38 minutes ago
Axe Compute Inc. to Ring Nasdaq Opening Bell Amid AI Infrastructure Growth and $3.45 Billion in Signed Contracts
Yahoo Finance
·
6 hours ago
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
Profile
Cerenome, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Cerenome also commercialized a molecular diagnostic service, CNSide®. Wikipedia
About Cerenome, Inc.